ArticleInfection and immunity2005
Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 73 citations in OpenAlex.
- Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing.Proceedings of the National Academy of Sciences of the United States of America · 2013Trial
- SigMine and OPathDb: a literature-mining pipeline and database of potential opportunistic pathogens.Archives of microbiology · 2026Article
- Metabiosis underlies a microbiota permissive to Pseudomonadota and increases the risk of gut-borne bloodstream infection.bioRxiv : the preprint server for biology · 2026Article
- Article
- Synthesis of polypyrrole/cellulose nanocrystals disks for removal of pyocyanin metabolite biomarker released by Pseudomonas aeruginosa.PloS one · 2025Article
- Production and Antibacterial Activity of Atypical Siderophore fromPharmaceuticals (Basel, Switzerland) · 2024Article
- Anticandidal Activity of a Siderophore from Marine EndophyteAntibiotics (Basel, Switzerland) · 2024Article
- Engineered live bacteria as disease detection and diagnosis tools.Journal of biological engineering · 2023Review
- Anti-Microorganisms · 2023Review
- T2SS-peptidase XcpA associated with LasR evolutional phenotypic variations provides a fitness advantage toFrontiers in microbiology · 2023Article
- Nanotoxoid vaccination protects against opportunistic bacterial infections arising from immunodeficiency.Science advances · 2022Article
- Innate and Adaptive Immune Responses againstVaccines · 2020Article
- Systemic infection facilitates transmission of Pseudomonas aeruginosa in mice.Nature communications · 2020Article
- An Invertebrate Burn Wound Model That Recapitulates the Hallmarks of Burn Trauma and Infection Seen in Mammalian Models.Frontiers in microbiology · 2020Article
- Metabolic output defines Escherichia coli as a health-promoting microbe against intestinal Pseudomonas aeruginosa.Scientific reports · 2019Article
- Fitting Pieces into the Puzzle ofJournal of bacteriology · 2019Review
- Article
- Adaptation ofCurrent clinical microbiology reports · 2018Article
- Pseudomonas aeruginosa flagellum is critical for invasion, cutaneous persistence and induction of inflammatory response of skin epidermis.Virulence · 2018Article
- Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.Antimicrobial agents and chemotherapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pseudomonas aeruginosa bacteremia in cancer patients develops from initial gastrointestinal (GI) colonization with translocation into the bloodstream in the setting of chemotherapy-induced neutropenia and GI mucosal damage. We established a reproducible mouse model of P. aeruginosa GI colonization and systemic spread during neutropenia. Mice received 2 mg of streptomycin/ml of drinking water and 1,500 U of penicillin G/ml for 4 days and then ingested 10(7) CFU of P. aeruginosa per ml of drinking water for 5 days. After GI colonization levels were determined, cyclophosphamide (Cy) was then injected intraperitoneally (i.p.) three times every other day or an antineutrophil monoclonal antibody, RB6-8C5, was injected i.p. once. Dissemination was defined by the presence of P. aeruginosa in spleens of moribund or dead mice. In this mouse model, P. aeruginosa colonizes the GI tract and then disseminates systemically once Cy or RB6-8C5 is administered. The duration and intensity of neutropenia, related to Cy dose, was found to be a means to compare the virulence of different P. aeruginosa strains, as exhibited by comparisons of strains lacking or producing the virulence-enhancing ExoU cytotoxin. The lipopolysaccharide outer core polysaccharide and O side chains were critical in establishing GI colonization, and P. aeruginosa mutants lacking the aroA gene (necessary for synthesizing aromatic amino acids) were able to establish GI colonization but unable to disseminate. Both the colonization and dissemination phases of P. aeruginosa pathogenesis can be studied in this model, which should prove useful for evaluating pathogenesis, therapies, and associated means to control P. aeruginosa nosocomial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.